Tennessee Oncology/Sarah Cannon Research Institute
Tennessee Oncology/Sarah Cannon Research Institute
Nashville, Tennessee, United States1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-10-02 | NCT02326974 |